Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco (Epi)genomics

IRVINE, CA, and LIEGE, BELGIUM -- (Marketwire) -- 11/30/12 -- MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that it has joined forces with the Ghent University to establish NXTGNT, a new Center in Pharmaco (Epi)genomics.

The mission of the Center is to accelerate innovation in personalized medicine by using advanced technology, knowledge and expertise in (epi)genetics. The Center will bring together scientific expertise from disease centered basic researchers, corresponding clinical validation teams, bioinformaticians, and cutting edge (epi)genomic technology focused on the discovery of effective individualized epigenetic-based diagnostic and personalized therapeutic products.

As a result of several years of productive collaboration between the Laboratory of Bioinformatics and Computational Genomics (BIOBIX), NXTGNT (UGent genome analysis facility), the Biomarked valorization consortium teams and MDxHealth, the new Center is located at Ghent University within the laboratory of Pharmaceutical Biotechnology. The facility will house MDxHealth's research team and lab equipment for development of epigenetic tests together with the Ghent University team for (epi)genetic sequencing. The facility works in close collaboration with the Laboratory of Bioinformatics and Computational Genomics, located at the Faculty of BioEngeneering, providing extensive expertise in epigenetic characterization and computing and visualization of (epi)genomic datasets. The Center is fully operational as off December 1, 2012.

"The creation of NXTGNT as a Center in Pharmaco (Epi)genomics is welcome advancement in the field of epigenetics and personalized medicine. There is a history of successful collaboration between MDxHealth and the University of Ghent, where much of the early epigenetics sequencing work on our biomarkers was conducted," said Dr. Jan Groen CEO of MDxHealth. "As more drugs are being developed alongside companion tests, there is a growing need for novel technologies, biomarkers and assays. We believe our experience in successfully developing personalized cancer epigenetic tests combined with the sequencing, bioinformatics and methylome analysis expertise contained in the new Center will prove extremely attractive to the pharmaceutical industry."

"The partners in NXTGNT and the University of Ghent have an established track record in biomarker research. Performing research towards technological advances, identification and validation of novel and more accurate biomarkers for risk stratification and prediction of therapy and our expertise in data-analysis and the development of new bioinformatic tools are an asset in this collaboration," Said Prof. Dieter Deforce from the University of Ghent, one of the NXTGNT partners. "By collaborating with MDxHealth we will ensure that results from our research in the collaboration field will be brought to the market in a more efficient way. Bringing the right partners together with the necessary contacts in the pharmaceutical industry will allow us to further advance in the field of personalized medicine."

About MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, the ConfirmMDx™ for Prostate Cancer test, has been shown to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth website at www.mdxhealth.com.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

PDF: http://hugin.info/137314/R/1661248/538157.pdf

For more information:

Dr. Jan Groen
CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com

Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955
Cell: +44 7968 022075
msinclair@halsin.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Enterprise Open Source Magazine Latest Stories . . .
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for vi...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into it...
I was experimenting with Java HashSet, which is a pretty expensive collection to create, but it has a benefit of the O(1) performance on the retrieval of elements from this collection. Based on my experiments performance of HashSet is improved over the last year. I’ve written a small ...
When I started exploring virtualization, like many folks, I was in awe of how much efficiency came with moving physical servers into VMs. To this day, the number of success stories about improved usage, reduced overhead costs and increased functionality makes virtualization a solid bus...
XebiaLabs has announced that XL Deploy, its Application Release Automation software, has received certification of its integration with ServiceNow. With XL Deploy from XebiaLabs, ServiceNow users can now easily automate the application deployment process so releases can occur in a re...
All enterprises, be they large or small, national or multinational, commercial or government agency, American or Chinese, Japanese or European, are carrying the dead weight of their history and almost certainly continuing to add unnecessary complexity and excessive cost that will progr...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE